In vitro study demonstrates tunable glucose-triggered insulin delivery using core-shell polymer microgels, highlighting a potential smart management platform for diabetes.
Intelligent insulin delivery systems have been a longstanding goal for effective diabetes management with minimized risk of hypoglycemia and reduced discomfort of finger pricks and injections. In this study, core-shell structured microgels are designed to regulate insulin release at physiologically relevant glucose levels. Specifically, a copolymer microgel of poly[(N-isopropylacrylamide)-co-acrylamide-co-(2-acrylamidomethyl-5-fluorophenylboronic acid)] [p(NIPAM-AAm-FPBA)] is prepared as the core to facilitate glucose sensitivity at physiological pH. The neutral hydrophilic poly[oligo(ethylene glycol) methyl ether methacrylate] (pOEGMA) gel shell is added onto the core microgel to enhance the insulin loading capacity and control the glucose-responsive properties of the resultant core-shell microgels. The thickness of the pOEGMA shell directly influences the glucose concentration required to initiate the volume phase transition of the core-shell microgels, allowing for tunable onset (or ‘gate’) of glucose-responsive insulin release. Insulin molecules remain encapsulated within the microgels under hypo- and normoglycemic conditions but are efficiently released in hyperglycemic conditions in response to elevated glucose levels. The pOEGMA-shelled microgels exhibit no cytotoxicity in vitro. Such core-shell microgels highlight their potential as an effective intelligent insulin delivery platform.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: